Mazeraud, A., Jamme, M., Mancusi, R. L., Latroche, C., Megarbane, B., Siami, S., Zarka, J., Moneger, G., Santoli, F., Argaud, L., Chillet, P., Muller, G., Bruel, C., Asfar, P., Beloncle, F., Reignier, J., Vinsonneau, C., Schimpf, C., Amour, J., Goulenok, C., Lemaitre, C., Rohaut, B., Mateu, P., De Rudnicki, S., Mourvillier, B., Declercq, P., Schwebel, C., Stoclin, A., Garnier, M., Madeux, B., Gaudry, S., Bailly, K., Lamer, C., Aegerter, P., Rieu, C., Sylla, K., Lucas, B., & Sharshar, T. (2022). intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet, 10(2), 158–166. http://access.bl.uk/ark:/81055/vdc_100150532318.0x00000c